questionText: To ask the Secretary of State for Health and Social Care, what steps the MHRA intends to take to consider patient and bereaved family lived experience as part of its current scientific review of Clozapine; and whether he is taking steps to ensure that lived experience actively shapes the committee's clinical determinations before key regulatory decisions have been made.
answerText: The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the ...
heading: Clozapine